Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study.

ABSTRACT:

Background

Sodium-glucose cotransporter 2 inhibitor (SGLT2i) should be considered for patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) having estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m² and urine albumin-to-creatinine ratio (UACR) > 30 mg/g. However, SGLT2i is currently underprescribed among eligible, at-risk patients for CKD progression. We analyzed prescription patterns and barriers to initiating SGLT2i in patients with T2D and CKD in real practice.

Methods

A total of 3,703 consecutive outpatients with T2D from four teaching hospitals during six months (2019 ~ 2020) were reviewed. Five eGFR categories (G1, ≥ 90; G2, 60-89; G3ab, 30-59; G4-5, < 30 mL/min/1.73 m²) and three UACR categories (A1, < 30; A2, 30-300; A

SUBMITTER: Jeong SJ 

PROVIDER: S-EPMC8122538 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature